Literature DB >> 8103249

Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome.

N W Thompson1, J Pasieka, A Fukuuchi.   

Abstract

Studies have shown that the duodenum is a more common site (30-40%) of primary gastrinomas than previously reported. These tumors are often occult to conventional exploration, and their detection requires duodenotomy and meticulous evaluation of the mucosa by eversion and direct palpation. Furthermore, tumors as small as 1 to 2 mm may be associated with lymph node metastases. Seven patients with duodenal gastrinomas treated during a 2-year period are reported. Four had sporadic Zollinger-Ellison syndrome (ZES), and three had multiple endocrine neoplasia type I (MEN-I) syndrome. All seven patients had malignant duodenal gastrinomas as proved by metastatic lymph nodes and in one case a large liver metastasis as well. Local excision of the tumor, lymph node excisions, and in one case liver lobectomy resulted in eugastrinemia in the 4 with sporadic ZES. Two of the three with MEN-I were also eugastrinemic after similar procedures, with the addition of distal pancreatectomy. Duodenotomy is considered an essential procedure in sporadic ZES patients when no pancreatic tumor is found and in all MEN-I/ZES patients, regardless of the pancreatic findings. Regional lymph node excisions are essential when a duodenal tumor has been found.

Entities:  

Mesh:

Year:  1993        PMID: 8103249     DOI: 10.1007/bf01655104

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  14 in total

1.  SURGICAL CONSIDERATION IN THE MANAGEMENT OF ULCEROGENIC TUMORS OF THE PANCREAS AND DUODENUM.

Authors:  H A OBERHELMAN; T S NELSEN
Journal:  Am J Surg       Date:  1964-08       Impact factor: 2.565

2.  Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation.

Authors:  J A Norton; D T Cromack; T H Shawker; J L Doppman; R Comi; P Gorden; P N Maton; J D Gardner; R T Jensen
Journal:  Ann Surg       Date:  1988-02       Impact factor: 12.969

3.  Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study.

Authors:  B C Sheppard; J A Norton; J L Doppman; P N Maton; J D Gardner; R T Jensen
Journal:  Surgery       Date:  1989-12       Impact factor: 3.982

4.  The surgical treatment of gastrinoma in MEN I syndrome patients.

Authors:  N W Thompson; A G Bondeson; L Bondeson; A Vinik
Journal:  Surgery       Date:  1989-12       Impact factor: 3.982

5.  Excisional therapy for ulcerogenic tumors of the duodenum: long-term results.

Authors:  H A Oberhelman
Journal:  Arch Surg       Date:  1972-04

6.  MEN I pancreas: a histological and immunohistochemical study.

Authors:  N W Thompson; R V Lloyd; R H Nishiyama; A I Vinik; W E Strodel; M D Allo; F E Eckhauser; G Talpos; T Mervak
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

7.  Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy.

Authors:  C Donow; M Pipeleers-Marichal; S Schröder; B Stamm; P U Heitz; G Klöppel
Journal:  Cancer       Date:  1991-09-15       Impact factor: 6.860

8.  The gastrinoma triangle: operative implications.

Authors:  B E Stabile; D J Morrow; E Passaro
Journal:  Am J Surg       Date:  1984-01       Impact factor: 2.565

9.  Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger-Ellison syndrome.

Authors:  N W Thompson; A I Vinik; F E Eckhauser
Journal:  Ann Surg       Date:  1989-04       Impact factor: 12.969

10.  Transhepatic portal vein catheterization for localization of sporadic and MEN gastrinomas: a ten-year experience.

Authors:  A I Vinik; A R Moattari; K Cho; N Thompson
Journal:  Surgery       Date:  1990-03       Impact factor: 3.982

View more
  14 in total

1.  [Rare occurrence of fulminant acid burn of the esophagus].

Authors:  C Knebel; R Bumm; K Becker; M Burian; J R Siewert
Journal:  Chirurg       Date:  2008-08       Impact factor: 0.955

Review 2.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Treatment of Zollinger-Ellison syndrome.

Authors:  M H Wheeler; M Sequeira
Journal:  J R Soc Med       Date:  1998-04       Impact factor: 5.344

Review 4.  Localization of gastrinomas.

Authors:  R A Prinz
Journal:  Int J Pancreatol       Date:  1996-04

Review 5.  Gastrinomas: Medical or Surgical Treatment.

Authors:  Jeffrey A Norton; Deshka S Foster; Tetsuhide Ito; Robert T Jensen
Journal:  Endocrinol Metab Clin North Am       Date:  2018-09       Impact factor: 4.741

Review 6.  [Multiple endocrine neoplasia Type I. Diagnosis and therapy in a case with classical family history].

Authors:  R Lamberts; M Gregor
Journal:  Med Klin (Munich)       Date:  1999-08-15

7.  Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?

Authors:  Jeffrey A Norton; H Richard Alexander; Douglas L Fraker; David J Venzon; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

Review 8.  Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.

Authors:  Paola Tomassetti; Teresa Salomone; Marina Migliori; Davide Campana; Roberto Corinaldesi
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study.

Authors:  Jeffrey A Norton; H Richard Alexander; Douglas L Fraker; David J Venzon; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

Review 10.  Surgical management of pancreatic endocrine tumors.

Authors:  Volker Fendrich; Jens Waldmann; Detlef K Bartsch; Peter Langer
Journal:  Nat Rev Clin Oncol       Date:  2009-06-09       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.